^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS

Published date:
11/04/2020
Excerpt:
Patient characteristics....somatic mutations...IDH1 mutation....Six patients were evaluable for disease response...3 pts (50%) had stable disease (with one patient having a 78% reduction in marrow blast count)....Single agent CFI-400945 has activity in patients with poor risk AML.
DOI:
https://doi.org/10.1182/blood-2020-138822